Skip to main content
PMC home page
Gut logoLink to Gut
. 2000 Sep;47(3):429–435. doi: 10.1136/gut.47.3.429

Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology

C Berasain 1, M Betes 1, A Panizo 1, J Ruiz 1, J Herrero 1, M Civeira 1, J Prieto 1
PMCID: PMC1728051  PMID: 10940283

Abstract

BACKGROUND—The histopathological spectrum and role of hepatitis viruses in cases of hypertransaminasaemia of unknown aetiology have not been correctly analysed in a sufficiently large number of patients.
METHODS—We studied 1075 consecutive patients referred for liver biopsy because of elevation of alanine aminotransferase (ALT) levels for more than six months. From this population we selected those cases in whom the aetiology could not be defined from clinical, biochemical, and serological data obtained before biopsy. In these patients liver biopsies were reviewed, and hepatitis B virus (HBV)-DNA and hepatitis C virus (HCV)-RNA were assayed in serum by polymerase chain reaction (PCR). Serum hepatitis G virus (HGV)-RNA was determined by PCR in 74 patients.
RESULTS—Of 1075 patients studied, the cause of the increased serum ALT levels remained elusive after appropriate testing in 109 patients (10.1%). Liver biopsies from these patients showed non-specific changes in 32.7% of cases, non-alcoholic steatohepatitis (NASH) in 15.8%, and chronic hepatitis or cirrhosis in 51.5%. HBV-DNA and/or HCV-RNA was detected more frequently in cryptogenic liver disease than in healthy blood donors (26.7% v 3.4%; p<0.001). HGV-RNA was found in only one patient. The proportion of cases with detectable HBV-DNA or HCV-RNA was 14.3% in patients with non-specific changes or NASH, 30.7% in patients with chronic hepatitis, and 61.5% in patients with cirrhosis. Cirrhosis was found more frequently in patients with positive HBV-DNA and/or HCV-RNA in serum than in those who tested negatively (p=0.005).
CONCLUSIONS—In our series, patients in whom biochemical and serological data did not determine the aetiology of the disease represented 10% of all cases referred for liver biopsy for persistent elevation of serum transaminases. Approximately 50% of patients had chronic hepatitis or cirrhosis and the remainder had NASH or non-specific changes. Occult viral infections were found in a high proportion of cases in the first group and in a low percentage of patients in the second.


Keywords: cryptogenic liver disease; cryptogenic hepatitis; hepatitis B virus; hepatitis C virus; hepatitis G virus; non-alcoholic steatohepatitis

Full Text

The Full Text of this article is available as a PDF (142.9 KB).

Figure 1  .

Figure 1  

Open in a new tab

Percentage of patients with cryptogenic liver disease and healthy controls who had detectable hepatitis B virus-DNA and/or hepatitis C virus-RNA by polymerase chain reaction in serum. NASH, non-alcoholic steatohepatitis.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bacon B. R., Farahvash M. J., Janney C. G., Neuschwander-Tetri B. A. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994 Oct;107(4):1103–1109. doi: 10.1016/0016-5085(94)90235-6. [DOI] [PubMed] [Google Scholar]
  2. Bahn A., Gerner P., Martiné U., Bortolotti F., Wirth S. Detection of different viral strains of hepatitis B virus in chronically infected children after seroconversion from HBsAg to anti-HBs indicating viral persistence. J Hepatol. 1997 Dec;27(6):973–978. doi: 10.1016/s0168-8278(97)80139-0. [DOI] [PubMed] [Google Scholar]
  3. Cacciola I., Pollicino T., Squadrito G., Cerenzia G., Orlando M. E., Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999 Jul 1;341(1):22–26. doi: 10.1056/NEJM199907013410104. [DOI] [PubMed] [Google Scholar]
  4. Chung H. T., Lai C. L., Lok A. S. Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. Hepatology. 1995 Jul;22(1):25–29. [PubMed] [Google Scholar]
  5. Czaja A. J. The variant forms of autoimmune hepatitis. Ann Intern Med. 1996 Oct 1;125(7):588–598. doi: 10.7326/0003-4819-125-7-199610010-00009. [DOI] [PubMed] [Google Scholar]
  6. Feitelson M. A., Duan L. X., Guo J., Sun B., Woo J., Steensma K., Horiike N., Blumberg B. S. X region deletion variants of hepatitis B virus in surface antigen-negative infections and non-A, non-B hepatitis. J Infect Dis. 1995 Sep;172(3):713–722. doi: 10.1093/infdis/172.3.713. [DOI] [PubMed] [Google Scholar]
  7. Fong T. L., Di Bisceglie A. M., Gerber M. A., Waggoner J. G., Hoofnagle J. H. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology. 1993 Dec;18(6):1313–1318. [PubMed] [Google Scholar]
  8. Fukuda R., Ishimura N., Kushiyama Y., Moriyama N., Ishihara S., Chowdhury A., Tokuda A., Sakai S., Akagi S., Watanabe M. Hepatitis B virus with X gene mutation is associated with the majority of serologically "silent" non-b, non-c chronic hepatitis. Microbiol Immunol. 1996;40(7):481–488. doi: 10.1111/j.1348-0421.1996.tb01098.x. [DOI] [PubMed] [Google Scholar]
  9. Geller S. A., Nichols W. S., Rojter S. E., Chan R. C., Petrovic L. M., Vierling J. M., Makowka L. Hepatitis C virus is not recoverable from liver tissue in cryptogenic cirrhosis: failure to identify hepatitis C virus-RNA using reverse transcription-mediated polymerase chain reaction. Hum Pathol. 1996 Nov;27(11):1161–1165. doi: 10.1016/s0046-8177(96)90309-3. [DOI] [PubMed] [Google Scholar]
  10. Gil B., Qian C., Riezu-Boj J. I., Civeira M. P., Prieto J. Hepatic and extrahepatic HCV RNA strands in chronic hepatitis C: different patterns of response to interferon treatment. Hepatology. 1993 Nov;18(5):1050–1054. [PubMed] [Google Scholar]
  11. Goldstein N. S., Kodali V. P., Gordon S. C. Histologic spectrum of cryptogenic chronic liver disease and comparison with chronic autoimmune and chronic type C hepatitis. Am J Clin Pathol. 1995 Nov;104(5):567–573. doi: 10.1093/ajcp/104.5.567. [DOI] [PubMed] [Google Scholar]
  12. Greeve M., Ferrell L., Kim M., Combs C., Roberts J., Ascher N., Wright T. L. Cirrhosis of undefined pathogenesis: absence of evidence for unknown viruses or autoimmune processes. Hepatology. 1993 Apr;17(4):593–598. doi: 10.1002/hep.1840170411. [DOI] [PubMed] [Google Scholar]
  13. Guilera M., Sáiz J. C., López-Labrador F. X., Olmedo E., Ampurdanés S., Forns X., Bruix J., Parés A., Sánchez-Tapias J. M., Jiménez de Anta M. T. Hepatitis G virus infection in chronic liver disease. Gut. 1998 Jan;42(1):107–111. doi: 10.1136/gut.42.1.107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hollingsworth R. C., Minton E. J., Fraser-Moodie C., Metivier E., Rizzi P. M., Irving W. L., Jenkins D., Ryder S. D. Hepatitis G infection: role in cryptogenic chronic liver disease and primary liver cell cancer in the UK. Trent Hepatitis C virus Study Group. J Viral Hepat. 1998 May;5(3):165–169. doi: 10.1046/j.1365-2893.1998.00102.x. [DOI] [PubMed] [Google Scholar]
  15. Huo T. I., Wu J. C., Lee P. C., Chau G. Y., Lui W. Y., Tsay S. H., Ting L. T., Chang F. Y., Lee S. D. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology. 1998 Jul;28(1):231–236. doi: 10.1002/hep.510280130. [DOI] [PubMed] [Google Scholar]
  16. Kodali V. P., Gordon S. C., Silverman A. L., McCray D. G. Cryptogenic liver disease in the United States: further evidence for non-A, non-B, and non-C hepatitis. Am J Gastroenterol. 1994 Oct;89(10):1836–1839. [PubMed] [Google Scholar]
  17. Liang T. J., Baruch Y., Ben-Porath E., Enat R., Bassan L., Brown N. V., Rimon N., Blum H. E., Wands J. R. Hepatitis B virus infection in patients with idiopathic liver disease. Hepatology. 1991 Jun;13(6):1044–1051. [PubMed] [Google Scholar]
  18. Loriot M. A., Marcellin P., Walker F., Boyer N., Degott C., Randrianatoavina I., Benhamou J. P., Erlinger S. Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. J Hepatol. 1997 Aug;27(2):251–258. doi: 10.1016/s0168-8278(97)80168-7. [DOI] [PubMed] [Google Scholar]
  19. Mathiesen U. L., Franzén L. E., Frydén A., Foberg U., Bodemar G. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol. 1999 Jan;34(1):85–91. doi: 10.1080/00365529950172880. [DOI] [PubMed] [Google Scholar]
  20. Paterlini P., Driss F., Nalpas B., Pisi E., Franco D., Berthelot P., Bréchot C. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology. 1993 Jan;17(1):20–29. [PubMed] [Google Scholar]
  21. Pessoa M. G., Terrault N. A., Detmer J., Kolberg J., Collins M., Hassoba H. M., Wright T. L. Quantitation of hepatitis G and C viruses in the liver: evidence that hepatitis G virus is not hepatotropic. Hepatology. 1998 Mar;27(3):877–880. doi: 10.1002/hep.510270335. [DOI] [PubMed] [Google Scholar]
  22. Romeo R., Pol S., Demeret C., Thiers V., Kremsdorf D., Cuillerier E., Berthelot P., Brechot C. Evidence of non-A, non-B, non-C infection in chronic hepatitis by polymerase chain reaction testing for hepatitis B and C viruses. J Hepatol. 1995 Feb;22(2):125–129. doi: 10.1016/0168-8278(95)80418-8. [DOI] [PubMed] [Google Scholar]
  23. Ruiz J., Sangro B., Cuende J. I., Beloqui O., Riezu-Boj J. I., Herrero J. I., Prieto J. Hepatitis B and C viral infections in patients with hepatocellular carcinoma. Hepatology. 1992 Sep;16(3):637–641. doi: 10.1002/hep.1840160305. [DOI] [PubMed] [Google Scholar]
  24. Sarrazin C., Herrmann G., Roth W. K., Lee J. H., Marx S., Zeuzem S. Prevalence and clinical and histological manifestation of hepatitis G/GBV-C infections in patients with elevated aminotransferases of unknown etiology. J Hepatol. 1997 Aug;27(2):276–283. doi: 10.1016/s0168-8278(97)80172-9. [DOI] [PubMed] [Google Scholar]
  25. Schmidt W. N., Wu P., Cederna J., Mitros F. A., LaBrecque D. R., Stapleton J. T. Surreptitious hepatitis C virus (HCV) infection detected in the majority of patients with cryptogenic chronic hepatitis and negative HCV antibody tests. J Infect Dis. 1997 Jul;176(1):27–33. doi: 10.1086/514033. [DOI] [PubMed] [Google Scholar]
  26. Sheth S. G., Gordon F. D., Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med. 1997 Jan 15;126(2):137–145. doi: 10.7326/0003-4819-126-2-199701150-00008. [DOI] [PubMed] [Google Scholar]
  27. Uchida T., Shimojima M., Gotoh K., Shikata T., Tanaka E., Kiyosawa K. "Silent" hepatitis B virus mutants are responsible for non-A, non-B, non-C, non-D, non-E hepatitis. Microbiol Immunol. 1994;38(4):281–285. doi: 10.1111/j.1348-0421.1994.tb01777.x. [DOI] [PubMed] [Google Scholar]
  28. Volta U., De Franceschi L., Lari F., Molinaro N., Zoli M., Bianchi F. B. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet. 1998 Jul 4;352(9121):26–29. doi: 10.1016/s0140-6736(97)11222-3. [DOI] [PubMed] [Google Scholar]
  29. Zhang Y. Y., Hansson B. G., Kuo L. S., Widell A., Nordenfelt E. Hepatitis B virus DNA in serum and liver is commonly found in Chinese patients with chronic liver disease despite the presence of antibodies to HBsAg. Hepatology. 1993 Apr;17(4):538–544. doi: 10.1002/hep.1840170403. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES